Ingalls & Snyder LLC’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$30.4M Sell
139,627
-857
-0.6% -$190K 1.07% 21
2025
Q4
$32.1M Sell
140,484
-4,543
-3% -$1.03M 1.18% 19
2025
Q3
$33.6M Buy
145,027
+7,966
+6% +$1.62M 1.1% 17
2025
Q2
$25.4M Buy
137,061
+344
+0.3% +$63.9K 0.9% 22
2025
Q1
$28.6M Sell
136,717
-1,031
-0.7% -$200K 0.94% 19
2024
Q4
$24.5M Sell
137,748
-1,892
-1% -$348K 0.96% 23
2024
Q3
$27.6M Sell
139,640
-9,823
-7% -$1.83M 1.08% 20
2024
Q2
$25.6M Sell
149,463
-2,516
-2% -$417K 1.1% 21
2024
Q1
$27.7M Sell
151,979
-2,588
-2% -$446K 1.22% 17
2023
Q4
$24M Sell
154,567
-9,198
-6% -$1.34M 1.08% 20
2023
Q3
$24.4M Sell
163,765
-3,258
-2% -$478K 1.18% 19
2023
Q2
$22.5M Sell
167,023
-1,363
-0.8% -$200K 1.08% 22
2023
Q1
$26.8M Sell
168,386
-38
-0% -$5.81K 1.38% 14
2022
Q4
$27.2M Sell
168,424
-1,837
-1% -$282K 1.48% 14
2022
Q3
$22.9M Sell
170,261
-1,255
-0.7% -$180K 1.28% 17
2022
Q2
$26.3M Sell
171,516
-2,594
-1% -$396K 1.37% 15
2022
Q1
$28.2M Sell
174,110
-8,749
-5% -$1.27M 1.26% 17
2021
Q4
$24.8M Buy
182,859
+3,044
+2% +$360K 1.12% 20
2021
Q3
$19.4M Sell
179,815
-7,655
-4% -$875K 0.89% 29
2021
Q2
$21.1M Buy
187,470
+549
+0.3% +$61.8K 0.94% 28
2021
Q1
$20.2M Buy
186,921
+5,804
+3% +$621K 0.94% 28
2020
Q4
$19.4M Buy
181,117
+9,569
+6% +$920K 0.96% 28
2020
Q3
$15M Buy
171,548
+15,421
+10% +$1.45M 1.03% 23
2020
Q2
$15.3M Buy
156,127
+11,158
+8% +$982K 0.88% 32
2020
Q1
$11M Buy
144,969
+23,562
+19% +$2.01M 0.74% 38
2019
Q4
$10.7M Sell
121,407
-1,115
-0.9% -$92.6K 0.58% 44
2019
Q3
$9.28M Buy
122,522
+51,946
+74% +$3.56M 0.45% 61
2019
Q2
$5.13M Sell
70,576
-45,468
-39% -$3.57M 0.25% 88
2019
Q1
$9.35M Buy
116,044
+2,733
+2% +$224K 0.45% 61
2018
Q4
$10.4M Sell
113,311
-2,953
-3% -$260K 0.55% 45
2018
Q3
$11M Sell
116,264
-1,164
-1% -$110K 0.46% 59
2018
Q2
$10.9M Sell
117,428
-1,795
-2% -$175K 0.5% 54
2018
Q1
$11.3M Buy
119,223
+677
+0.6% +$74.4K 0.55% 47
2017
Q4
$11.5M Sell
118,546
-918
-0.8% -$86.5K 0.53% 50
2017
Q3
$10.6M Buy
119,464
+44,054
+58% +$3.35M 0.55% 44
2017
Q2
$5.47M Buy
75,410
+1,254
+2% +$84.3K 0.3% 70
2017
Q1
$4.83M Buy
74,156
+1,517
+2% +$95.4K 0.26% 74
2016
Q4
$4.55M Sell
72,639
-25,575
-26% -$1.56M 0.25% 82
2016
Q3
$6.19M Sell
98,214
-3,848
-4% -$249K 0.35% 62
2016
Q2
$6.32M Buy
102,062
+964
+1% +$58.7K 0.37% 57
2016
Q1
$5.77M Sell
101,098
-3,791
-4% -$211K 0.37% 55
2015
Q4
$6.21M Buy
104,889
+23,677
+29% +$1.36M 0.4% 54
2015
Q3
$4.42M Buy
81,212
+394
+0.5% +$25.6K 0.29% 69
2015
Q2
$5.43M Sell
80,818
-1,531
-2% -$100K 0.3% 69
2015
Q1
$4.82M Sell
82,349
-13,213
-14% -$798K 0.27% 71
2014
Q4
$6.25M Sell
95,562
-1,788
-2% -$113K 0.36% 60
2014
Q3
$5.62M Sell
97,350
-502
-0.5% -$27.9K 0.3% 63
2014
Q2
$5.52M Sell
97,852
-300
-0.3% -$15.7K 0.27% 71
2014
Q1
$5.04M Buy
98,152
+11
+0% +$556 0.27% 71
2013
Q4
$5.18M Sell
98,141
-770
-0.8% -$37.8K 0.29% 66
2013
Q3
$4.42M Sell
98,911
-2,740
-3% -$121K 0.26% 70
2013
Q2
$4.2M Buy
+101,651
New +$4.45M 0.27% 71

Other funds holding ABBV

Ingalls & Snyder LLC's ABBV Position: Q1 2026 in Review

Ingalls & Snyder LLC reduced its AbbVie (ABBV) stake by 0.61% in Q1 2026, selling an estimated $190K and leaving 139,627 shares worth $30.4M. The position accounts for 1.07% of the portfolio, ranked #21.

Ingalls & Snyder LLC first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $33.6M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Ingalls & Snyder LLC held 139,627 shares of AbbVie worth $30.4M as of Q1 2026.
  • Ingalls & Snyder LLC sold 857 AbbVie shares in Q1 2026, an estimated $190K.
  • AbbVie made up 1.07% of Ingalls & Snyder LLC's portfolio in Q1 2026, its #21 holding.
  • Ingalls & Snyder LLC first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Ingalls & Snyder LLC's AbbVie position peaked at $33.6M in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q1 2026, filed 13 May 2026.